CRIS Current Research Information System

MASSARI, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 11.844
NA - Nord America 5.988
EU - Europa 3.919
SA - Sud America 1.062
AF - Africa 492
OC - Oceania 12
Continente sconosciuto - Info sul continente non disponibili 6
Totale 23.323
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.878
SG - Singapore 3.868
CN - Cina 3.639
VN - Vietnam 1.518
HK - Hong Kong 1.162
IT - Italia 1.066
BR - Brasile 838
KR - Corea 802
GB - Regno Unito 474
SE - Svezia 416
DE - Germania 408
IN - India 388
NL - Olanda 345
CH - Svizzera 215
RU - Federazione Russa 210
SC - Seychelles 199
IE - Irlanda 159
FI - Finlandia 155
FR - Francia 146
CI - Costa d'Avorio 131
JP - Giappone 131
AR - Argentina 106
ID - Indonesia 95
AT - Austria 69
ZA - Sudafrica 59
BG - Bulgaria 57
CA - Canada 53
TG - Togo 48
JO - Giordania 46
MX - Messico 39
PL - Polonia 35
UA - Ucraina 35
EC - Ecuador 33
BD - Bangladesh 32
TR - Turchia 30
EE - Estonia 29
ES - Italia 26
VE - Venezuela 23
BE - Belgio 20
IQ - Iraq 19
CO - Colombia 18
PK - Pakistan 17
CL - Cile 16
NG - Nigeria 15
MY - Malesia 13
AU - Australia 12
PY - Paraguay 12
UZ - Uzbekistan 12
PT - Portogallo 10
KE - Kenya 9
LT - Lituania 9
AZ - Azerbaigian 8
TN - Tunisia 8
TW - Taiwan 8
UY - Uruguay 8
PE - Perù 7
AE - Emirati Arabi Uniti 6
IL - Israele 6
PH - Filippine 6
SA - Arabia Saudita 6
AL - Albania 5
EG - Egitto 5
GR - Grecia 5
HR - Croazia 5
IR - Iran 5
KZ - Kazakistan 5
MA - Marocco 5
LB - Libano 4
TH - Thailandia 4
XK - ???statistics.table.value.countryCode.XK??? 4
DO - Repubblica Dominicana 3
HN - Honduras 3
LV - Lettonia 3
NP - Nepal 3
RO - Romania 3
TT - Trinidad e Tobago 3
BH - Bahrain 2
BY - Bielorussia 2
CD - Congo 2
CY - Cipro 2
CZ - Repubblica Ceca 2
GH - Ghana 2
HU - Ungheria 2
IS - Islanda 2
JM - Giamaica 2
KG - Kirghizistan 2
MD - Moldavia 2
PS - Palestinian Territory 2
RS - Serbia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BW - Botswana 1
CR - Costa Rica 1
DZ - Algeria 1
EU - Europa 1
GD - Grenada 1
GN - Guinea 1
Totale 23.310
Salva come PNG Salva come JPEG
Città #
Singapore 2.636
Hefei 1.770
Hong Kong 1.152
Seoul 799
Ashburn 764
Boardman 482
Ho Chi Minh City 393
Santa Clara 384
Fairfield 374
Southend 355
Hanoi 335
Beijing 322
Chandler 311
Bologna 214
Bern 207
Los Angeles 206
Seattle 179
Bengaluru 165
Wilmington 161
Woodbridge 159
Dublin 158
Houston 141
Abidjan 131
Cambridge 129
Princeton 127
Dong Ket 122
Milan 122
Dallas 119
Tokyo 117
Buffalo 112
Redondo Beach 107
Helsinki 104
São Paulo 77
New York 74
Boydton 73
Ann Arbor 69
Jakarta 61
Nuremberg 60
Guangzhou 58
Turin 57
Sofia 55
Tongling 54
Da Nang 53
Shanghai 50
Lomé 48
Rome 47
Amman 46
Castel Maggiore 46
Chicago 45
Nanjing 43
Lappeenranta 41
Redmond 36
Vienna 36
Westminster 36
Berlin 33
Florence 33
Frankfurt am Main 33
Munich 32
Biên Hòa 30
Falkenstein 30
Amsterdam 28
Changsha 28
Haiphong 28
Hyderabad 26
Rio de Janeiro 26
Jinan 25
San Diego 25
Padova 24
Redwood City 24
Ha Long 23
Quận Bình Thạnh 23
Ninh Bình 22
Paris 22
Warsaw 22
Yubileyny 22
Zhengzhou 22
Hải Dương 21
Brooklyn 20
Montreal 20
Boston 19
Brussels 19
Shenyang 19
Thái Nguyên 19
Bắc Ninh 18
Phoenix 18
Moscow 17
Tianjin 17
Vũng Tàu 17
Belo Horizonte 16
Brasília 16
Curitiba 16
Elk Grove Village 16
Falls Church 16
Stockholm 16
Denver 15
Des Moines 15
Hangzhou 15
San Francisco 15
Xi'an 15
London 14
Totale 15.012
Salva come PNG Salva come JPEG
Nome #
Predictors of outcome for patients with lung adenocarcinoma carrying the epidermal growth factor receptor mutation receiving 1st-line tyrosine kinase inhibitors: Sensitivity and meta-regression analysis of randomized trials 242
First-line Systemic Therapy Following Adjuvant Immunotherapy in Renal Cell Carcinoma: An International Multicenter Study 235
Multi-Gene Next-Generation Sequencing Panel for Analysis of BRCA1/BRCA2 and Homologous Recombination Repair Genes Alterations Metastatic Castration-Resistant Prostate Cancer 232
A case of complete response to nivolumab after long-term progression-free survival with tyrosine kinase inhibitor. 206
Circulating tumor cells in genitourinary tumors 190
Adrenal Insufficiency with Anticancer Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor Receptor: Analysis of the FDA Adverse Event Reporting System 181
H&E and OCT4/CD34 for the assessment of lympho-vascular invasion in seminoma and embryonal carcinoma 168
Clinical management of a pituitary gland metastasis from clear cell renal cell carcinoma. 168
INTRAHEPATIC CHOLANGIOCARCINOMA DEVELOPMENT IN A PATIENT WITH A NOVEL BAP1 GERMLINE MUTATION AND LOW EXPOSURE TO ASBESTOS 168
223Ra-chloride therapy in men with hormone-refractory prostate cancer and skeletal metastases: Real-world experience. 164
Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience 161
Liver metastases from prostate cancer at 11C-Choline PET/CT: a multicenter, retrospective analysis 157
CARE-compliant stereotactic radiotherapy of urothelial nodal metastases: A case report 156
Sopravvivenza di pazienti con recidiva vaginale di carcinoma endometriale: il ruolo della radioterapia e della chirurgia. 150
Cabozantinib-related cardiotoxicity: a prospective analysis in a "real world" cohort of metastatic renal cell carcinoma patients 150
Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer 148
Immune checkpoint inhibitors for metastatic bladder cancer 142
Insights into the impact of chromosome 3p mutations in advanced renal cell carcinoma treated with immune-based combinations or targeted therapy: A single-center experience 141
Oestrogen receptor 1 mRNA is a prognostic factor in ovarian cancer patients treated with neo-adjuvant chemotherapy: determination by array and kinetic PCR in fresh tissue biopsies. 141
Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer 139
Bone targeting agents in patients with metastatic prostate cancer: State of the art 137
Bone targeting agents, but not radiation therapy, improves survival in patients with bone metastases from advanced urothelial carcinoma receiving pembrolizumab: results from the ARON-2 study 137
Broad spectrum mutational analysis of chromophobe renal cell carcinoma using next-generation sequencing 136
Circulating Tumor Cells: A Reliable Biomarker for Prostate Cancer Treatment Assessment? 133
New Hormonal Agents in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: Meta-Analysis of Efficacy and Safety Outcomes. 132
Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2 Retrospective Experience 130
Wide spetcrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach 129
A hypothesis-generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy 128
Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw 127
Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations 126
A prospective study on the early evaluation of response to androgen receptor-targeted agents with 11C-Choline, 68Ga-PSMA, and 18F-FACBC PET in metastatic castration-resistant prostate cancer: a single-center experience 126
Analysis of GATA3 and FOXA2 expression suggests that downregulation of genes involved in the maintenance of a mature yolk sac tumor phenotype may underlie sarcomatoid transformation 125
Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study 124
Prognostic Factors of Survival for High-Grade Neuroendocrine Neoplasia of the Bladder: A SEER Database Analysis 124
TAMs PD-L1(+) in the reprogramming of germ cell tumors of the testis 124
Targeting the Programmed Cell Death-1 Pathway in Genitourinary Tumors: Current Progress and Future Perspectives 124
Tumor growth rate to assess therapy response to immune-based combinations for metastatic renal cell carcinoma 123
The Tumor Entity Denominated “clear cell-papillary renal cell carcinoma” According to the WHO 2016 new Classification, have the Clinical Characters of a Renal Cell Adenoma as does Harbor a Benign Outcome 123
Chemotherapy in metastatic renal cell carcinoma today? A systematic review 123
The value of molecular features in predicting efficacy of immuno-combinations in kidney cancer: just a drop in the ocean? 122
Detection of liver lesions during 11C-Choline PET/CT in relapsing prostate cancer patients 122
Immune-checkpoint inhibitors in previously treated patients with advanced or metastatic urothelial carcinoma: A systematic review and meta-analysis 122
The human microbiota and prostate cancer: Friend or foe? 122
Mutations of NOTCH Genes as an Alternative Mechanism to Activate mTOR pathway in Low-grade Oncocytic Tumor (LOT) of the Kidney 119
Dual-energy spectral CT in renal cell carcinoma: dawn of a brand-new era? 119
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study 118
FoxA2 is a reliable marker for the diagnosis of yolk sac tumour postpubertal-type 118
Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study 117
Immune modulation in prostate cancer patients treated with androgen receptor (Ar)-targeted therapy 117
Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer 115
Mirna Expression in Bladder Cancer and Their Potential Role in Clinical Practice 114
Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study 113
Urinary biomarkers for prostate cancer 113
Is There a Role for Immunotherapy in Prostate Cancer? 113
Narrative review of prostate cancer grading systems: Will the Gleason scores be replaced by the grade groups? 112
Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier? 112
Hypertransaminasemia in metastatic renal cell carcinoma patients receiving immune-based combinations: a meta-analysis 111
The prospect of precision therapy for renal cell carcinoma. 111
A Meta-Analysis Evaluating Clinical Outcomes of Patients with Renal Cell Carcinoma Harboring Chromosome 9P Loss. 111
Immortal time bias question in the association between toxicity and outcome of immune checkpoint inhibitors 111
Adjuvant therapy in renal cell carcinoma: Is it the right strategy to inhibit VEGF? 110
Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics 110
Expected and non-expected immune-related adverse events detectable by CT 110
Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial 109
Development and validation of a new tool to estimate early mortality in patients with advanced cancer treated with immunotherapy 109
Immunohistochemical over-expression of HER2 does not always match with gene amplification in invasive bladder cancer 109
Prognostic and predictive factors in patients treated with chemotherapy for advanced urothelial cancer: Where do we stand? 107
Similarities and differences between clear cell tubulo-papillary and conventional clear cell renal cell carcinoma: A comparative phenotypical and mutational analysis 107
Genomics and Immunomics in the Treatment of Urothelial Carcinoma 106
State of the art of adjuvant immunotherapy in urothelial cancer: New developments and upcoming changes 106
BAP1 in solid tumors 105
Impact of HER2 assessment by CISH in urothelial carcinoma: A retrospective single-center experience 104
Update on circulating tumor cells in genitourinary tumors with focus on prostate cancer 103
First-line immune-based combinations or sunitinib in favorable-risk metastatic renal cell carcinoma: a real-world retrospective comparison from the ARON-1 study 103
Should CARMENA Really Change our Attitude Towards Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cytoreductive Nephrectomy in the Era of Targeted Therapy. 103
Evaluation of an institutional series of low-grade oncocytic tumor (LOT) of the kidney and review of the mutational landscape of LOT 102
Prostate cancer heterogeneity: Discovering novel molecular targets for therapy 102
Tumor growth rate decline despite progressive disease may predict improved nivolumab treatment outcome in mrcc: When recist is not enough 102
Sex as modifier of survival in patients with advanced urothelial cancer treated with pembrolizumab 101
Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib 101
Novel Immune Checkpoint Inhibitor Targets in Advanced or Metastatic Renal Cell Carcinoma: State of the Art and Future Perspectives 100
New prostate cancer targets for diagnosis, imaging, and therapy: Focus on prostate-specific membrane antigen 99
Avelumab Plus Intermittent Axitinib in Previously Untreated Patients with Metastatic Renal Cell Carcinoma. The Tide-A Phase 2 Study 99
Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: A meta-analysis 98
The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System 95
Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1) 94
Metabolomic profiling in renal cell carcinoma patients: News and views 93
Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer 93
Belzutifan: enhancing the blockade of angiogenesis in renal cell carcinoma 93
Circulating tumor dna testing for homology recombination repair genes in prostate cancer: From the lab to the clinic 92
Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial 92
Renal Tumors with Oncocytic and Papillary Features: A Phenotypic and Genotypic Study 92
Body mass index in patients treated with cabozantinib for advanced renal cell carcinoma: A new prognostic factor? 91
Sex differences in adverse events among cancer patients receiving immune checkpoint inhibitors: the MOUSEION-07 systematic review and meta-analysis 91
Key role of obesity in genitourinary tumors with emphasis on urothelial and prostate cancers 91
Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors 91
Addition of Primary Metastatic Site on Bone, Brain, and Liver to IMDC Criteria in Patients With Metastatic Renal Cell Carcinoma: A Validation Study 91
Resistance to systemic agents in renal cell carcinoma predict and overcome genomic strategies adopted by tumor 90
Re: Robert J. Motzer, Alain Ravaud, Jean-Jacques Patard, et al. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2017.09.008 90
Characterization of testicular embryonic-type neuroectodermal tumor and embryonic-type neuroectodermal tissue admixed with mature neuro-glial tissue using a broad immunohistochemical panel 89
Totale 12.275
Salva come PNG Salva come JPEG
Categoria #
all - tutte 83.607
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 83.607
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021578 0 0 0 0 0 7 26 36 95 44 29 341
2021/20221.091 46 33 41 81 88 56 41 101 133 47 282 142
2022/20232.575 112 151 59 169 214 460 212 129 388 70 228 383
2023/20241.133 131 171 94 95 84 140 37 93 56 91 73 68
2024/20257.012 209 688 728 406 851 255 453 209 224 428 828 1.733
2025/202610.167 2.136 2.466 2.287 1.684 1.516 78 0 0 0 0 0 0
Totale 24.183